Hematologic side effects of immune checkpoint inhibitor with or without chemotherapy in patients with advanced and metastatic gastrointestinal cancer: A systematic review and network meta-analysis of phase 3 trials

Background: The regimens of immune checkpoint inhibitors (ICIs) alone or with chemotherapy are emerging as systemic therapy for patients with advanced and metastatic gastrointestinal cancers. However, the risk of treatment-related hematologic toxicity stays unclear. Methods: We enrolled in phase 3 r...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Jingyi, Xie, Ruiyang, Zhang, Zhuo, Liu, Qianxin, Xiang, Qian, Cui, Yimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073573/
https://www.ncbi.nlm.nih.gov/pubmed/37033653
http://dx.doi.org/10.3389/fphar.2023.1163971

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073573/
https://www.ncbi.nlm.nih.gov/pubmed/37033653
http://dx.doi.org/10.3389/fphar.2023.1163971

Ejemplares similares